As small-cap stocks gain traction amid a broader market rotation out of Big Tech stocks, here are two market underdogs poised for explosive growth, according to analysts.
Why Shares of Tarsus Pharmaceuticals Are Up Thursday
The company's lead therapy is getting close to the finish line of FDA approval.
Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease
IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...
Tarsus to Present at the Jefferies 2022 Healthcare Conference
IRVINE, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...
Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements
TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; anticipated NDA submission in the second half of this year ...